Small molecule · Inhibitor of KIT proto-oncogene receptor tyrosine kinase (KIT) and platelet derived growth factor receptor alpha (PDGFRA) · developed by Deciphera Pharms
Ripretinib is an orally bioavailable tyrosine kinase inhibitor that binds the switch pocket of wild-type and mutated KIT and PDGFRA, preventing their activation and blocking tumor cell signaling. It also inhibits several other kinases, including VEGFR2, TIE2 and PDGFRB. It is used in gastrointestinal stromal tumor (GIST).
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of May 12, 2025). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04633122 | Phase 2 | Gastrointestinal Stromal Tumor(GIST) | Completed | ZLAB |
| NCT04282980 | Phase 2 | Gastrointestinal Stromal Tumors | Completed | ZLAB |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Gastrointestinal Stromal Tumors
Updated Nov 1, 2026.